Many people who turn to compounded GLP-1 drugs do so without proper medical guidance, putting themselves at unnecessary risk
Separate-Vial Reconstitution Spec BAC water added BPC-157 (10 mg vial) 2.0 mL TB-500 (10 mg vial) 2.0 mL Spec Final concentration BPC-157 (10 mg vial) 5.0 mg/mL TB-500 (10 mg vial) 5.0 mg/mL Spec 10 units (0.10 mL) delivers BPC-157 (10 mg vial) 500 mcg TB-500 (10 mg vial) 500 mcg Spec 20 units (0.20 mL) delivers BPC-157 (10 mg vial) 1.0 mg TB-500 (10 mg vial) 1.0 mg Spec Doses per vial (typical) BPC-157 (10 mg vial) ~2040 days TB-500 (10 mg vial) ~45 loading doses This separate-vial row keeps the same 10 mg-per-compound assumption as the 20 mg pre-blend, but the compounds are reconstituted and drawn independently
And so we start looking into it, and it turns out that it's prevalent in mother's milk, and it's a very unstable molecule, but we all have a receptor for it
Citi: In a scenario where GLP-1s benefit a large number of people, there could be a gradual increase in the available labor force due to reduction in musculoskeletal issues and chronic diseases, boosting both GDP and tax revenue. Whats more, a Goldman Sachs analysis from earlier this year estimates that GLP-1 drugs could boost GDP by 0.4 percent in its baseline scenario, with potential gains up to one percent in its upside case
It raises blood sugar by signaling the liver to release stored glucose